Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dovramilast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B known ✓ | Q07343 | 20/20 | 0.59 |
| ▸ | PDE4C known ✓ | Q08493 | 18/20 | 0.59 |
| ▸ | PDE4A known ✓ | P27815 | 12/20 | 0.59 |
| ▸ | PDE4D known ✓ | Q08499 | 12/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dovramilast SCHEMBL30701938 | 1.00 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL15869364 | 1.00 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL827461 | 1.00 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL14983202 | 1.00 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL29366888 | 1.00 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL15869363 | 1.00 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL15869345 | 0.95 | PDE4B (0.53) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL15869344 | 0.95 | PDE4B (0.53) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL15580958 | 0.95 | PDE4B (0.53) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL15869347 | 0.94 | PDE4B (0.56) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313818-B1 | METHODS FOR THE TREATMENT OF KAPOSI'S SARCOMA OR KSHV-INDUCED LYMPHOMA USING IMMUNOMODULATORY COMPOUNDS, AND USES OF BIOMARKERS | CELGENE CORP (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-2555769-B1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | AMGEN EUROPE GMBH (CH) | 2022-01-12 | — | — | EP | disclosed |
| EP-3899539-A1 | PARTICLE BASED SMALL MOLECULE-PROTEIN COMPLEX TRAP | Orionis Biosciences, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3827836-A1 | COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES | Celgene Corporation (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-3320902-B1 | METHODS FOR TREATING DISEASES USING ISOINDOLINE COMPOUNDS | AMGEN EUROPE GMBH (CH) | 2021-02-17 | — | — | EP | disclosed |
| EP-3320902-B1 | METHODS FOR TREATING DISEASES USING ISOINDOLINE COMPOUNDS | AMGEN EUROPE GMBH (CH) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020132189-A1 | PARTICLE BASED SMALL MOLECULE-PROTEIN COMPLEX TRAP | ORIONIS BIOSCIENCES, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-10682336-B2 | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) | AMGEN INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10682336-B2 | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) | AMGEN INC. (US) | 2020-06-16 | — | — | US | disclosed |
| EP-2765993-B1 | FORMULATIONS OF CYCLOPROPANECARBOXYLIC ACID {2-[(1S)-1-(3-ETHOXY-4-METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL]-3-OXO-2, 3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE | AMGEN EUROPE GMBH (CH) | 2020-05-20 | — | — | EP | disclosed |
| WO-2009120296-A1 | TREATMENT OF PSORIASIS OR PSORIATIC ARTHRITIS USING CYCLOPROPYL-N-{2-{(1S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYLSULFONYL)ETHYL]-3-OXOISOINDOLINE-4-YL}CARBOXAMIDE | CELGENE CORPORATION (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090239926-A1 | METHODS FOR THE TREATMENT OF PSORIASIS OR PSORIATIC ARTHRITIS USING CYCLOPROPYL-N-CARBOXAMIDE | CELGENE CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239926-A1 | METHODS FOR THE TREATMENT OF PSORIASIS OR PSORIATIC ARTHRITIS USING CYCLOPROPYL-N-CARBOXAMIDE | CELGENE CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20080221196-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION | 2008-09-11 | — | — | US | disclosed |
| US-20080221196-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION | 2008-09-11 | — | — | US | disclosed |
| US-20080138295-A1 | Bechet's disease using cyclopropyl-N-carboxamide | CELGENE COPORATION | 2008-06-12 | — | — | US | disclosed |
| US-20080138295-A1 | Bechet's disease using cyclopropyl-N-carboxamide | CELGENE COPORATION | 2008-06-12 | — | — | US | disclosed |
| US-7354948-B2 | Methods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide | CELGENE CORPORATION (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354948-B2 | Methods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide | CELGENE CORPORATION (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070155791-A1 | Methods for treating cutaneous lupus using aminoisoindoline compounds | CELGENE CORPORATION | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221196-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | PDE3A, PDE2A, PDE5A | PDE4B 10/4885PDE4C 8/4885PDE4A 6/4885 |
| US-20070155791-A1 | Methods for treating cutaneous lupus using aminoisoindoline compounds | SSB, ARG2, ARGLU1 | PDE4B 2118/4885PDE4C 2322/4885PDE4A 2497/4885 |
| US-20080138295-A1 | Bechet's disease using cyclopropyl-N-carboxamide | IL2, TNF, FGF2 | PDE4B 754/4885PDE4C 1092/4885PDE4A 786/4885 |
| US-20090239926-A1 | METHODS FOR THE TREATMENT OF PSORIASIS OR PSORIATIC ARTHRITIS USING CYCLOPROPYL-N-CARBOXAMIDE | TPMT, PAICS, CHUK | PDE4B 842/4885PDE4C 512/4885PDE4A 587/4885 |
| US-10682336-B2 | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) | PDE4A, PDE4B, PDE3A | PDE4B 2/4885PDE4C 5/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.